GalA(a1-6)Glc(b)-O-octyl

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: GalA(a1-6)Glc(b)-O-octyl
• 英文别名: (2S,3R,4S,5R,6S)-3,4,5-trihydroxy-6-[[(2R,3S,4S,5R,6R)-3,4,5-trihydroxy-6-octoxyoxan-2-yl]methoxy]oxane-2-carboxylic acid
• 化学式: C₂₀H₃₆O₁₂
• 分子量: 468.5
• InChiKey: YVHXIHIZVYXSLT-XJUFJQLESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  32
• 可旋转键数：
  12
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  196
• 氢给体数：
  7
• 氢受体数：
  12

文献信息

• IMPROVED PEPTIDE PHARMACEUTICALS
  申请人：EUMEDERIS PHARMACEUTICALS, INC.

  公开号：US20150307550A1

  公开（公告）日：2015-10-29

  Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.

  本文描述了共价修饰肽和/或蛋白质的合成方法和治疗用途。共价修饰的肽和/或蛋白质可以改善基于肽和蛋白质的治疗药物的药理特性。
• PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE
  申请人：MEDERIS DIABETES LLC

  公开号：US20150290334A1

  公开（公告）日：2015-10-15

  Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.

  本文描述了合成和治疗用途的共价修饰肽和/或蛋白质的方法。这些共价修饰的肽和/或蛋白质可以改善肽和蛋白质治疗药物的药理特性。
• IMPROVED PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE
  申请人：Mederis Diabetes, LLC

  公开号：EP3434696A1

  公开（公告）日：2019-01-30

  Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.

  本文描述了共价修饰肽和/或蛋白质的合成方法和治疗用途。共价修饰的肽和/或蛋白质可改善基于肽和蛋白质的疗法的药物特性。
• Peptide pharmaceuticals
  申请人：EUMEDERIS PHARMACEUTICALS, INC.

  公开号：US10005817B2

  公开（公告）日：2018-06-26

  Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.

  本文描述了共价修饰肽和/或蛋白质的合成方法和治疗用途。共价修饰的肽和/或蛋白质可改善基于肽和蛋白质的疗法的药物特性。
• Peptide pharmaceuticals for insulin resistance
  申请人：Mederis Diabetes LLC

  公开号：US10577405B2

  公开（公告）日：2020-03-03

  Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.

  本文描述了共价修饰肽和/或蛋白质的合成方法和治疗用途。共价修饰的肽和/或蛋白质可改善基于肽和蛋白质的疗法的药物特性。